Phase 2 N=38 Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
Cervical Squamous Cell Carcinoma · Recurrent Cervical Carcinoma
Primary: Progression-free Survival Greater Than 6 Months — 30; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)
Gaucher Disease
Primary: Evaluation of Long Term Safety — 0; 10; 1; 1 Participants
Phase 2 N=58 Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Disease Control Rate (Stable Disease or Objective Response) — 53; 53 percentage of participants
Phase 2 N=20 Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
Polypoidal Choroidal Vasculopathy
Primary: Commonly Reported and Notable Adverse Events — 1; 2; 2; 3 participants
Phase 2 N=361 Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 — -0.46; -0.25; -0.71; -1.08 Percentage of HbA1c in the blood — p=0.2968
Phase 2 N=121 Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Adenocarcinoma of the Prostate · Hormone-refractory Prostate Cancer · Recurrent Prostate Cancer
Primary: Proportion of Patients With PSA Response — 0.293; 0.098; 0.042 Proportion of participants
Phase 2 N=18 Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata
Alopecia Areata
Primary: Mean Change in Cortisol Levels From Baseline to Week 24 — 0.187 mg/dL
Phase 2 N=5 Safety and Efficacy of CC-10004 for Prurigo Nodularis
Prurigo Nodularis
Primary: Improvement in Prurigo Nodularis — 0; 2 participants
Phase 2 N=17 Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
EBV Viremia · CMV Viremia
Primary: Incidence of EBV or CMV Related Disease in Transplant Recipient — 2; 0 participants
Phase 2 N=54 Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
Multiple Myeloma · Lymphocytic Leukemia, Chronic · Lymphoma, Low-Grade
Primary: Percentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-4 — 73 percentage of participants
Phase 2 N=25 Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
Wilms Tumor · Fibrosarcoma · Carcinoma, Round Cell
Primary: Percent of Participants With Progression Free Survival at 1 Year — 58 percentage of participants
Phase 2 N=41 Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Complete Response Rate — 10 percentage of participants
Phase 2 N=40 The Efficacy and Safety of Hypertonic Saline in Cardiac Surgery Patients.
Coronary Artery Disease · Edema
Primary: Extravascular Lung Water Index — 9; 8; 9; 8 mL/kg
Phase 2 N=34 Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
Lung Injury, Acute · Respiratory Distress Syndrome, Adult · Bronchiolitis Obliterans
Primary: Percent of Patients With a Greater Than or Equal to 10% Improvement in FEV1, or FVC, and DLCO — 32; 16 percent evaluable participants
Phase 2 N=601 Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
Prevention of Meningococcal Disease
Primary: Percentages of Subjects With hSBA Titers ≥ 1:4 Against N. Meningitidis Serogroups A, C, W, and Y Following 3 Doses of MenACWY Ad+ Vaccine — 6; 0; 93; 81 percentages of…